MDxHealth (MDXH) sells 44M shares, lifting total stock to 95.4M
Rhea-AI Filing Summary
MDxHealth SA completed a Registered Direct Offering, issuing 44,052,862 ordinary shares at $0.454 per share to several institutional investors. The transaction was conducted directly, without a placement agent, and closed on August 13, 2026, generating approximately $20.0 million in net proceeds before offering expenses.
The company plans to use these proceeds for working capital and general corporate purposes, including funding product development and expanding commercialization activities. MDxHealth amended its Articles of Association to reflect the related capital increase, bringing total outstanding ordinary shares to 95,417,382 after the offering.
Positive
- None.
Negative
- None.
Key Figures
Shares issued: 44,052,862 ordinary shares
Offering price: $0.454 per share
Net proceeds: Approximately $20.0 million
+2 more
5 metrics
Shares issued
44,052,862 ordinary shares
Aggregate number of new shares sold in the Registered Direct Offering
Offering price
$0.454 per share
Purchase price per ordinary share in the Registered Direct Offering
Net proceeds
Approximately $20.0 million
Net proceeds from the offering before deducting offering expenses
Post-offering shares outstanding
95,417,382 ordinary shares
Total number of outstanding ordinary shares after the capital increase
Capital increase date
August 13, 2026
Date Articles of Association were amended for the 44,052,862 share increase
Key Terms
Registered Direct Offering, shelf registration statement, Form F-3, Articles of Association, +1 more
5 terms
Registered Direct Offering financial
"at a purchase price per share of $0.454 (the “Registered Direct Offering”)"
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
shelf registration statement regulatory
"pursuant to a “shelf” registration statement on Form F-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
Form F-3 regulatory
"pursuant to a “shelf” registration statement on Form F-3"
Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.
Articles of Association regulatory
"amended its Articles of Association to account for a capital increase"
A company's articles of association are its written rulebook that sets how the business is run, how decisions are made, and what rights owners and directors have—covering voting, meetings, appointment and removal of directors, share classes and dividend policies. For investors, these rules matter because they determine how easily control can change, what protections minority owners have, and how corporate actions (like issuing new shares or changing leadership) are approved, much like a home’s bylaws shaping what residents can and cannot do.
Securities Purchase Agreements financial
"entered into Securities Purchase Agreements with several institutional investors"
A securities purchase agreement is a legal contract that spells out the terms when a company sells stocks, bonds, or other investment instruments to buyers. It lays out price, how many securities change hands, any promises or protections for each side, and when the sale is completed—like a detailed sales contract for investments. Investors care because it determines ownership stakes, potential dilution, rights attached to the securities, and conditions that affect the company’s future value.
Offering Details
shelf
Offering
Offering Type
shelf
Use of Proceeds
Working capital and general corporate purposes, including funding product development efforts and expansion of commercialization activities
FAQ
What capital raise did MDXH complete in August 2026?
MDxHealth SA completed a Registered Direct Offering, issuing 44,052,862 ordinary shares at $0.454 per share to institutional investors. The offering closed on August 13, 2026, under an effective Form F-3 shelf registration.
How will MDXH use the proceeds from the August 2026 capital raise?
MDxHealth SA intends to use the approximately $20.0 million in net proceeds for working capital and general corporate purposes. This includes funding the company’s product development efforts and supporting the expansion of its commercialization activities.
Under what registration did MDXH conduct the August 2026 offering?
The offering was conducted under an effective Form F-3 shelf registration statement (File No. 333-292463). The ordinary shares were sold only by means of a prospectus and prospectus supplement forming part of this registration statement.
Did MDXH use an underwriter or placement agent for the August 2026 deal?
No. MDxHealth SA states that the ordinary shares were offered directly to investors without a placement agent, underwriter, broker or dealer. The terms were documented in Securities Purchase Agreements containing customary representations, warranties, conditions, and indemnification provisions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
